- Home
- BIIB vs TME Comparison
BIIB vs TME Comparison
Compare BIIB & TME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TME
- Stock Information
- Founded
- BIIB 1978
- TME N/A
- Country
- BIIB United States
- TME China
- Employees
- BIIB N/A
- TME N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TME Broadcasting
- Sector
- BIIB Health Care
- TME Consumer Discretionary
- Exchange
- BIIB Nasdaq
- TME Nasdaq
- Market Cap
- BIIB 19.9B
- TME 21.9B
- IPO Year
- BIIB 1991
- TME 2018
- Fundamental
- Price
- BIIB $125.59
- TME $16.63
- Analyst Decision
- BIIB Buy
- TME Strong Buy
- Analyst Count
- BIIB 27
- TME 6
- Target Price
- BIIB $201.26
- TME $15.00
- AVG Volume (30 Days)
- BIIB 1.6M
- TME 7.1M
- Earning Date
- BIIB 05-01-2025
- TME 05-13-2025
- Dividend Yield
- BIIB N/A
- TME 1.08%
- EPS Growth
- BIIB 26.39
- TME 84.42
- EPS
- BIIB 10.12
- TME 0.84
- Revenue
- BIIB $9,816,400,000.00
- TME $3,994,901,125.00
- Revenue This Year
- BIIB N/A
- TME $10.12
- Revenue Next Year
- BIIB N/A
- TME $10.51
- P/E Ratio
- BIIB $12.43
- TME $19.52
- Revenue Growth
- BIIB 1.59
- TME 5.35
- 52 Week Low
- BIIB $110.04
- TME $9.41
- 52 Week High
- BIIB $238.00
- TME $15.77
- Technical
- Relative Strength Index (RSI)
- BIIB 55.21
- TME 71.70
- Support Level
- BIIB $119.18
- TME $13.30
- Resistance Level
- BIIB $124.82
- TME $17.05
- Average True Range (ATR)
- BIIB 3.81
- TME 0.62
- MACD
- BIIB 1.21
- TME 0.32
- Stochastic Oscillator
- BIIB 98.29
- TME 88.82
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TME Tencent Music Entertainment Group each representing two
Tencent Music is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.